the rhucin phase 3 data
The 28-patient Phase III trial for the orphan indication of hereditary angioedema was stopped early on August 20 on the advice of EU regulators because the magnitude of benefit of Rhucin made it unethical to keep some patients on placebo.
The interim results showed that Rhucin-treated patients reported their first relief of symptoms (the primary endpoint) at a median time of 60 minutes compared with 8.5 hours for those who received placebo, with a highly significant p-value of 0.0009.
In addition, patients on Rhucin had minimal symptoms at a median time of 6.1 hours compared with 20.2 hours for patients on placebo (p=0.0038)
The analysis demonstrated that 100% of the Rhucin patients responded to treatment and had sustained relief without a relapse of their attack symptoms, said Pharming.
the cynryse phase 3 data
, with a median time to sustained symptom relief of 2.0 hours for patients receiving C1-INH compared to greater than four hours, the maximum evaluation period, for patients receiving placebo (p=0.026)
I would prefer the recombitant form of the drug as opposed to pooled plasma even if equivalent. but I think it has an advantage.
The market cap is cheap considering where they are in Europe.
I do not know why every argument has to have a winner. I do not own the stock but the more I am writing about it and looking into it the more I think I will buy some next week.
try not to be so stressed.
News 
Market Data 
Discover 
